Replies to post #538 on Axim Biotechnologies Inc (AXIM)

[Triple9]

AXIM has multiple patents.

The market value is based on the patents alone. Just about everyone else releases PRs saying "we filed a provisional patent...", meanwhile, AXIM continues to be granted patents:

https://globenewswire.com/news-release/2017/10/05/1141427/0/en/New-U-S-Patent-Allowance-Granted-to-AXIM-Biotechnologies-Inc-for-Cannabinoid-Ophthalmic-Solutions-for-Glaucoma-and-Conjunctivitis-Treatment.html

This is the reason the stock took off:

http://www.ipwatchdog.com/2017/01/08/axim-biotech-patent-chewing-gum-cannabinoids-treat-neurodegenerative-diseases/id=76159/

And the Company has been featured in Forbes twice.

Pure Speculation: Say that cannabis is legalized in the US in 2020. Altria moves into the space in a big way, gobbling up Canopy and Aurora using pocket change from the couch. How much does Altria pay AXIM for its patents for CBD gum?